Schering AG/Epix Vasovist (MS-325)
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA is asking Epix "to consider a re-read of the images from the Phase III trials to provide additional information about the usefulness of dynamic versus steady state images, and to schedule a meeting with the FDA to discuss the merits and design of such a study," the company says July 1. The firm announced that FDA accepted its May 23 "complete response" to a January "approvable" letter, setting a user fee goal date of Nov. 23. However, "Epix' response did not include efficacy data from new clinical trials, which were requested by the FDA to demonstrate efficacy prior to approval in the…approvable letter," Epix explained. CEO Michael Webb acknowledged that Epix is "not yet in agreement with the FDA," but has maintained that the complete response addresses the agency's concerns (1Pharmaceutical Approvals Monthly June 2005, p. 5)...
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.